{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'For operational issues, contact the Head of', 'For operational issues, contact the Head of', 'Operationsoperationallead listed below:', 'Operations listed below:', 'Section 1.3.2 Clinical Studies (other section affected: Section 1.3.2.1 Clinical Pharmacology Studies)', 'The clinical development plan for TEV-50717 to date', 'The clinical development plan for TEV-50717 to date', 'The clinical development plan for', 'includes:', 'includes:', 'TEV-50717 has been updated to', '67 completed Phase 1 studies in healthy adult', '7 completed Phase 1 studies in healthy adult', 'reflect the most current program', 'subjects', 'subjects', 'information.', '2 ongoing Phase 1 studies in healthy adult', '2 ongoing Phase 1 studies in healthy adult', 'volunteers', 'volunteers', '1 completed Phase 3 pivotal study for the', '1 completed Phase 3 pivotal study for the', 'treatment of chorea associated with HD', 'treatment of chorea associated with HD', '1 completed Phase 3 long-term safety study', '1 completed Phase 3 long-term safety study', 'in patients with HD', 'in patients with HD', '198']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justificatior for change', '2 completed Phase 2/3 and Phase 3 studies in', '2 completed Phase 2/3 and Phase 3 studies in', 'patients with TD', 'patients with TD', '1 ongoing Phase 3 long-term safety study in', '1 ongoing Phase 3 long-term safety study in', 'patients with TD', 'patients with TD', '1 completed Phase 1b study in patients with', '1 completed Phase 1b study in patients with', 'TS', 'TS', '2 ongoing Phase 2/3 and Phase 3 studies in', '2 ongoing Phase 2/3 and Phase 3 studies in', 'patients with TS', 'patients with TS', '1 ongoing Phase 3 long-term safety study in', '1 ongoing Phase 3 long-term safety study in', 'patients with TS', 'patients with TS', 'Section 2.3.3 Exploratory Enppoints (other sections affected: Section 9.5.3 Exploratory Enppoints and Section 9.5.4.4 Exploratory', 'Analyses)', 'Update on and addition of the', 'exploratory endpoints evaluating', 'reduction', 'Section 3.1.2 Screening Period', 'Patients may be rescreened 1 time if there is a change', 'Patients may be rescreened 1 time if there is a change', 'Provided further details about', \"in the patient's medical background, a\", 'in the status of the patient regarding eligibility for the', 'rescreening activities and process', 'modificationstatus of the patient regarding eligibility', 'study.', 'for the study-entry criteria, or other relevant change.', 'Section 3.3.3 Exploratory Measures and Time Points', 'Update on and addition of the', 'exploratory measures and time', 'points evaluating reduction', '199']['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'Protocol Amendment 04 text with changes shown', 'New wording', 'Reason/Justification for change', 'Section 3.7.2 Blinding/Unblinding', 'When a blind is broken, the patient will be withdrawn', 'When a blind is broken, the patient will be', 'Provided further guidance to the', 'from the study, and the event will be recorded onto', 'withdrawn from the study, and the event will be', 'investigator in the situation that a', 'the case report form (CRF). However, if a patient is', 'recorded onto the case report form (CRF). However,', 'patient is unblinded by mistake', 'unblinded by mistake, the investigator should discuss', 'if a patient is unblinded by mistake, the investigator', 'with the medical monitor whether or not the patient', 'should discuss with the medical monitor whether or', 'should be withdrawn.', 'not the patient should be withdrawn.', 'Section 3.9.1 Drug Storage and Security', 'The IMP (TEV-50717 and placebo) should be stored', 'The IMP (TEV-50717 and placebo) should be stored', 'Updated temperature range for', 'protected from light, at a controlled room', 'protected from light, at a controlled room', 'storage of the IMP', 'temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); however,', 'temperature, 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F); however,', 'storage between 15\u00b0C and 3020\u00b0C (59\u00b0F and 8668\u00b0F)', 'storage between 15\u00b0C and 20\u00b0C (59\u00b0F and 68\u00b0F) is', 'is acceptable if there is no alternative.', 'acceptable if there is no alternative.', 'Section 3.13.1 Procedures for Screening and Enrollment (other sections affected: Section 3.13.2 Procedures Before IMP Treatment', '(Baseline/Day 1), Section 3.13.3.1.2 Clinic Visits (Weeks 2, 4, and 6), Section 3.13.3.2.1 Week 9, Section 3.13.3.2.2', 'Week', '12/Early', 'Termination, Section 3.13.4.1 Week 13, and Section 3.13.5 Unscheduled Visits)', 'A signed and dated informed consent form will be', 'A signed and dated informed consent form will be', 'Updated language surrounding', 'obtained from the parent/legally acceptable', 'obtained from the parent/legally acceptable', 'who can be involved in the', 'representative (may also include an adult other than a', 'representative, and a signed and dated assent,', 'informed consent/assent process.', 'parent or legal representative), and a signed and dated', \"depending on the child's age, as appropriate, will be\", 'Removed a parenthetical', \"assent, depending on the child's age, as appropriate,\", 'obtained from each patient before screening', 'expression that was inserted', 'will be obtained from each patient before screening', 'procedures commence, according to national laws', 'previously', 'procedures commence, according to national laws', 'and local IEC/IRB requirements. Parents/legally', 'Included \"conduct clinic visit\"', 'and local IEC/IRB requirements. Parents/legally', 'acceptable representatives will acknowledge and', 'strictly for clarity at each visit', 'acceptable representatives will acknowledge and', 'agree to the possible use of this information for the', 'where patients are expected to be', 'agree to the possible use of this information for the', 'study by giving informed consent.', 'present at the clinic for', 'study by giving informed consent.', 'assessment', 'A patient who is screened but not enrolled may be', 'A patient who is screened but not enrolled may be', \"rescreened 1 time if there is a change in the patient's\", '200']\n\n###\n\n", "completion": "END"}